Interpreting Key Trials

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Mark E. Mayer, MD
Women’s Health Section, Department of General Internal Medicine, Cleveland Clinic

Address: Mark E. Mayer, MD, Department of General Internal Medicine, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mayerm@ccf.org

Mark E. Mayer, MD
Women’s Health Section, Department of General Internal Medicine, Cleveland Clinic

Address: Mark E. Mayer, MD, Department of General Internal Medicine, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mayerm@ccf.org

Mark E. Mayer, MD
Women’s Health Section, Department of General Internal Medicine, Cleveland Clinic

Address: Mark E. Mayer, MD, Department of General Internal Medicine, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mayerm@ccf.org

Gary W. Falk, MD
Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic

Address: Gary W. Falk, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; falkg@ccf.org

Gary W. Falk, MD
Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic

Address: Gary W. Falk, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; falkg@ccf.org

Gary W. Falk, MD
Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic

Address: Gary W. Falk, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; falkg@ccf.org

Christian E. Nasr, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Byron J. Hoogwerf, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Charles Faiman, MD
Chairman, Department of Endocrinology, and Metabolism, Cleveland Clinic

S. Sethu K. Reddy, MD
Department of Endocrinology, and Metabolism, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Christian E. Nasr, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Byron J. Hoogwerf, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Charles Faiman, MD
Chairman, Department of Endocrinology, and Metabolism, Cleveland Clinic

S. Sethu K. Reddy, MD
Department of Endocrinology, and Metabolism, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Christian E. Nasr, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Byron J. Hoogwerf, MD
Department of Endocrinology and Metabolism, Cleveland Clinic

Charles Faiman, MD
Chairman, Department of Endocrinology, and Metabolism, Cleveland Clinic

S. Sethu K. Reddy, MD
Department of Endocrinology, and Metabolism, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.

Vasant B. Patel, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Vasant B. Patel, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Vasant B. Patel, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Beth A. Overmoyer, MD
Assistant Professor of Medicine, Case Western Reserve University School of Medicine; Director, Breast Cancer Research Program, Ireland Cancer Center, University Hospitals of Cleveland

Address: Beth A. Overmoyer, MD, Ireland Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106

Beth A. Overmoyer, MD
Assistant Professor of Medicine, Case Western Reserve University School of Medicine; Director, Breast Cancer Research Program, Ireland Cancer Center, University Hospitals of Cleveland

Address: Beth A. Overmoyer, MD, Ireland Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106

Beth A. Overmoyer, MD
Assistant Professor of Medicine, Case Western Reserve University School of Medicine; Director, Breast Cancer Research Program, Ireland Cancer Center, University Hospitals of Cleveland

Address: Beth A. Overmoyer, MD, Ireland Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106

Michael L. Macknin, MD
Chairman, Department of General Pediatrics, Cleveland Clinic; researcher in several studies of zinc in treating colds

Address: Michael L. Macknin, MD, Department of General Pediatrics, A120, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Macknin owns stock in the Quigley Corporation, a manufacturer of zinc lozenges.

Michael L. Macknin, MD
Chairman, Department of General Pediatrics, Cleveland Clinic; researcher in several studies of zinc in treating colds

Address: Michael L. Macknin, MD, Department of General Pediatrics, A120, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Macknin owns stock in the Quigley Corporation, a manufacturer of zinc lozenges.

Michael L. Macknin, MD
Chairman, Department of General Pediatrics, Cleveland Clinic; researcher in several studies of zinc in treating colds

Address: Michael L. Macknin, MD, Department of General Pediatrics, A120, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Macknin owns stock in the Quigley Corporation, a manufacturer of zinc lozenges.

Robert E. Hobbs, MD
Section of Heart Failure/Transplant, Department of Cardiology, Cleveland Clinic

Address: Robert E. Hobbs, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Robert E. Hobbs, MD
Section of Heart Failure/Transplant, Department of Cardiology, Cleveland Clinic

Address: Robert E. Hobbs, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Robert E. Hobbs, MD
Section of Heart Failure/Transplant, Department of Cardiology, Cleveland Clinic

Address: Robert E. Hobbs, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Matthew T. Roe, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic; medical director, angiographic core laboratory, EPILOG trial

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Matthew T. Roe, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic; medical director, angiographic core laboratory, EPILOG trial

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Matthew T. Roe, MD
Department of Cardiology, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic; medical director, angiographic core laboratory, EPILOG trial

Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195